Bimatoprost

NEW YORK — In this presentation from OSN New York, Nathan M. Radcliffe, MD, shares pearls for effective use of the Durysta implant for treating glaucoma.

WAIKOLOA, Hawaii — At Hawaiian Eye 2022, I. Paul Singh, MD, discusses some of the advantages of the use of Durysta intracameral bimatoprost injection to lower IOP in patients with glaucoma.

NEW YORK — Sustained-release drug delivery for glaucoma treatment offers a way to reduce IOP without relying on surgery or drops and gives physicians a way to customize treatment plans for individual patients, according to a speaker here.

LAS VEGAS — Patients with glaucoma showed high response rates after receiving a bimatoprost implant to reduce IOP, according to research presented at the American Society of Cataract and Refractive Surgery meeting.

WAILEA, Hawaii — In this video at Hawaiian Eye 2021, Savak Teymoorian, MD, MBA, discusses how the Durysta bimatoprost implant 10 µg from Allergan obviates the need for patients with glaucoma to instill drops.

Some patients treated with a bimatoprost slow-release implant over 1 year can maintain the IOP-lowering effect without relapse for 2 years or even 4 years after the last administration, according to a study.

Due to COVID-19, my practice only saw urgent or emergent patients at risk of going blind for 3 months in early 2020. Once we began to accept patients for routine in-person visits again, we worked to optimize treatment for a COVID-19 world.

Patients with glaucoma who displayed an early treatment response to a 10 µg bimatoprost implant and experienced greater than 20% IOP lowering at 12 weeks had significantly greater odds of a long-term IOP response, according to a speaker.

In this Healio Video Perspective from the virtual AAO annual meeting, Michael R. Robinson, MD, discusses patient characteristics affecting long-term IOP-lowering effects after implantation of Durysta (bimatoprost implant, AbbVie).

During a most unexpected and challenging year, ophthalmic practices are looking for reasons to celebrate.